Harnessing the Healing Power of Bone Marrow-Derived Cells for Chronic Low Back Pain

Chronic low back pain (CLBP) is a prevalent and debilitating condition that affects millions of individuals worldwide, significantly impacting their quality of life and productivity. Traditional treatments often provide only temporary relief, leaving patients searching for more effective and long-lasting solutions. In recent years, regenerative medicine has emerged as a promising approach to addressing the underlying causes of CLBP, with bone marrow-derived cells showing particular potential. A recent study titled “Evaluation of the Effectiveness of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Chronic Low Back Pain Due to Severe Lumbar Spinal Degeneration” highlights the positive outcomes of utilizing patients’ own bone marrow-derived cells to alleviate CLBP. Let’s delve into how this innovative therapy works and the implications of the study’s findings.

The Promise of Bone Marrow-Derived Cells:

Bone marrow serves as a rich source of mesenchymal stem cells (MSCs), multipotent cells capable of differentiating into various cell types, including bone, cartilage, and adipose tissue. MSCs also possess potent anti-inflammatory and immunomodulatory properties, making them attractive candidates for regenerative therapies. In the context of CLBP, MSCs hold promise for promoting tissue repair and regeneration within the degenerated spinal discs and surrounding structures.

The Study: A Game-Changer for CLBP Treatment?

The study referenced, a 12-month, open-label, prospective controlled trial, evaluated the effectiveness of autologous bone marrow-derived MSCs in treating CLBP due to severe lumbar spinal degeneration. In this groundbreaking trial, patients underwent a minimally invasive procedure in which their own bone marrow-derived cells were harvested, processed, and then injected into the affected spinal discs, facet joints, and sacroiliac joints (SIJs). The results were nothing short of remarkable, with patients experiencing significant improvements in pain, function, and quality of life over the course of the study.

Key Findings:

  1. Pain Reduction: Patients treated with autologous bone marrow-derived MSCs reported substantial reductions in low back pain, with many experiencing a significant improvement in pain scores compared to baseline. This reduction in pain was sustained throughout the 12-month follow-up period, indicating the long-lasting benefits of the therapy.
  2. Functional Improvement: Beyond pain relief, participants also demonstrated improvements in functional outcomes, including increased mobility, reduced disability, and enhanced quality of life. These improvements were particularly evident in activities of daily living and occupational tasks, allowing patients to resume their normal routines with greater ease and comfort.
  3. Safety and Tolerability: Importantly, the treatment was well-tolerated by patients, with no serious adverse events reported during the study period. This favorable safety profile underscores the potential of autologous bone marrow-derived MSC therapy as a safe and effective treatment option for CLBP.

Implications for Clinical Practice

The findings of this study have significant implications for the management of CLBP and underscore the potential of regenerative medicine approaches in revolutionizing treatment paradigms. By harnessing the regenerative properties of bone marrow-derived MSCs, clinicians can offer patients a promising alternative to traditional therapies, with the potential for long-term pain relief and functional improvement.


Chronic low back pain poses a significant burden on individuals and healthcare systems worldwide, highlighting the urgent need for more effective treatment options. The study evaluating the effectiveness of autologous bone marrow-derived MSCs represents a significant milestone in the field of regenerative medicine, offering hope to millions of CLBP sufferers. As research in this area continues to evolve, it is clear that bone marrow-derived cell therapies hold immense promise for transforming the landscape of CLBP treatment, paving the way for a future where pain relief and functional restoration are achievable goals for all patients.

  1. Kirchner F, Anitua E. Intradiscal and intra articular facet infiltrations with plasma rich in growth factors reduce pain in patients with chronic low back pain. J Craniovert Jun Spine 2016;7:250-6.
About The Author
James Leiber, DO Medically Reviewed By Ignatios Papas, DO

James Leiber, DO Medically Reviewed By Ignatios Papas, DO

James Leiber, DO Medically Reviewed By Ignatios Papas, DO

James Leiber, DO Medically Reviewed By Ignatios Papas, DO

Related Posts

Follow Us

Recent Posts

Are You a Regenexx® Candidate?

Subscribe to our blog
This field is for validation purposes and should be left unchanged.
Download Our Free Non-Surgical Regenerative Orthopedics Ebook

"*" indicates required fields

This field is for validation purposes and should be left unchanged.